Abstract: The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer, pancreatic cancer, colon cancer, melanoma, hepatoma and adenocarcinoma. Particularly, compositions and methods involving administration, either simultaneously or sequentially, of pharmaceutical combinations comprising (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1 -(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide with other compounds, to patients suffering from cancer are described.

Abstract: Nutritional compositions, formulations, and intermediates are provided which may be utilized to formulate various sweeteners and other products. The formulations described herein are made from constituents found in soils or fossilized soils.

Abstract: A method of preparing a compound of formula (III): (M)x-(S)y-(M?)z??(III) wherein x is from 1 to 6, y is from 1 to 12, z is from 0 to 10, each M and each M? is independently a mycolic acid residue including a ?-hydroxy acid moiety and each S is a monosaccharide unit; the method comprising reacting one or more mycolic acids with one or more saccharide units wherein the hydroxyl group of each ?-hydroxy acid moiety is protected prior to reaction with the one or more saccharide units.

Abstract: Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: the various substituents of which are defined herein.

Abstract: The invention relates to the treatment of metabolic disorders in an overweight or obese patient characterized in that empagliflozin and one or more antiobesity drugs are administered to the patient.

Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.

Abstract: A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.

Abstract: A method for manufacturing a modified hydroxyethyl starch carrying a heptonic acid residue on at least one of its termini is disclosed. Within this method, the following steps are carried out: a) dissolving hydroxyethyl starch in water, b) adjusting the pH value to a value of 8.0 to 10.0, c) adding a cyanide compound to the hydroxyethyl starch solution, heating the solution to a temperature of 80 to 99° C. and keeping it at this temperature for a first time period, and d) adjusting the pH value to a value of 2.0 to 4.0, bringing the solution to a temperature of 50 to 90° C. and keeping it at this temperature for a second time period.

Abstract: This invention relates to a cationically and amphiphilically modified polygalactomannan having repeating units with an average D-mannosyl to D-galactosyl residue ratio of at least 5 to 1 and to compositions containing same. A portion of the hydrogen atoms of hydroxyl groups situated on the mannosyl and galactosyl residues of the galactomannan are replaced with an amphiphilic and a cationic substituent.

Abstract: The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis.

Abstract: A process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functional groups, in an aqueous phase, which includes the following steps: a polysaccharide is placed in an aqueous medium, it is brought into the presence of at least one precursor of a substituent, it is brought into the presence of a crosslinking agent, the substituted and crosslinked polysaccharide is obtained and isolated, wherein process is carried out in the presence of a basic or acidic catalyst, the concentration of which is between 3.16×10?7 and 0.32 mol/L, and at a temperature of less than 60° C. In one embodiment, the polysaccharide is in the form of a gel or hydrogel which is used in particular as augmentation biomaterial.

Abstract: Provided herein are water-soluble carbohydrate polymers which are monoderivatized at their reducing terminus, such that the carbohydrate polymers can be selectively conjugated at a single location. Also provided are methods of preparation and conjugation of the monoderivatized carbohydrate polymers.

Abstract: The invention comprises compounds, methods of making, and methods of using. The compounds may have a backbone and three appended functional groups: one lipid, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. A variety of linkers between the backbone and functional groups may also be selected to optimize performance.

Abstract: Disclosed is a method of treating pain. The method includes administering a lecithin as an active ingredient to a mammal to treat the pain, wherein the pain is caused by at least one of herpes zoster, post-herpetic neuralgia, and diabetic neuropathic pain. The method further includes administering at least one selected from the group consisting of vegetable gel, a vegetable resin, and a synthetic resin, wherein the vegetable gel, vegetable resin, and synthetic resin is selected from the group consisting of aloe gel; a seaweed extract selected from the group consisting of kelp extract, agar extract, and Fucoidan; and a mixture thereof.

Abstract: Method for producing 5-hydroxymethylfurfural (HMF), wherein a) solutions (hereinbelow called starting solution) which comprise a hexose and an organic solvent with a boiling point greater than 200° C. (at standard pressure) (for short called high-boiling component), and steam are fed to a reaction vessel, b) in the reaction vessel, a conversion of the hexose to HMF takes place in the presence of steam with the simultaneous distillative removal of the HMF and c) as distillate, an aqueous, HMF-comprising solution (hereinbelow called distillate) is obtained.

Abstract: A process for preparing 5-hydroxymethylfurfural (HMF), which comprises a) feeding solutions (hereinafter called starting solution) comprising one or more saccharides and an organic solvent having a boiling point greater than 200° C. (at standard pressure) (called high boiler for short) and water, ?and a solvent having a boiling point greater than 60° C. and less than 200° C. (at standard pressure, called low boiler for short) to a reaction vessel, b) effecting a conversion of hexose to HMF in the reaction vessel in the presence of water vapor with simultaneous distillative removal of the HMF and c) obtaining, as the distillate, an aqueous, HMF-comprising solution (hereinafter called distillate).

Abstract: The present invention provides for a composition comprising a solution comprising (a) an ionic liquid (IL) or ionic liquid-aqueous (ILA) phase and (b) an organic phase, wherein the solution comprises a sugar and a boronic acid. The present invention also provides for a method of removing a sugar from a solution, comprising: (a) providing a solution comprising (i) an IL or ILA phase and (ii) an organic phase, wherein the solution comprises an IL, a sugar and a boronic acid; (b) contacting the sugar with the boronic acid to form a sugar-boronic acid complex, (c) separating the organic phase and the aqueous phase, wherein the organic phase contains the sugar-boronic acid complex, and optionally (d) separating the sugar from the organic phase.

Abstract: Method for producing solutions which comprise 5-hydroxymethylfurfural (HMF) and have a reduced content of starting materials of the HMF synthesis or a reduced content of by-products of the HMF synthesis (hereinbelow called product solution), which comprises treating solutions which comprise HMF starting materials or by-products of the HMF synthesis and an organic solvent having at least two ether groups (for short polyether) (hereinbelow called starting solution) in an evaporator with steam.

Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.

Abstract: The invention discloses a cross-linked polymer of at least one carbohydrate component comprising at least one primary alcohol function in particular for the manufacture of a composition which is intended to be applied onto the skin to obtain a tensing and/or toning effect.